STOCK TITAN

Quince Therapeutics (QNCX) DEF 14A Filings

QNCX NASDAQ

Ticker history: QNCX became IRLA (IRulya Therapeutics Inc.) on .

Here are the DEF 14A proxy statements from Quince Therapeutics, Inc. (QNCX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow QNCX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full QNCX filings page.

Rhea-AI Summary

Quince Therapeutics, Inc. (symbol: QNCX) is the issuer of record for a Form DEF 14A filing submitted to the SEC.

Rhea-AI Summary

Quince Therapeutics, Inc. is holding a virtual 2026 annual stockholder meeting on June 11, 2026 at 10:00 a.m. Pacific Time to vote on several key proposals.

Stockholders will elect one Class I director, consider a major reverse stock split of common stock at a ratio between 1-for-10 and 1-for-100, and vote on ratifying BDO USA, P.C. as auditor for 2026. They will also cast an advisory vote on executive compensation and approve potential adjournment to solicit more proxies. Stockholders of record as of April 23, 2026, when 16,300,740 common shares were outstanding, are entitled to vote.